Cleo Diagnostics (ASX:COV) Cash Flow from Others : A$2.13 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Cash Flow from Others?

Cleo Diagnostics's cash flow from others for the six months ended in Dec. 2023 was A$1.29 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2023 was A$2.13 Mil.

Cleo Diagnostics Cash Flow from Others Historical Data

The historical data trend for Cleo Diagnostics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Cash Flow from Others Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Cash Flow from Others

1.00

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Cash Flow from Others	0.16	0.85	1.29

Cleo Diagnostics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.13 Mil.

Cleo Diagnostics Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Cash Flow from Others

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines